ArticleInternational journal of hematology2014
Hepcidin and GDF15 in anemia of multiple myeloma.
Article in International journal of hematology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 34 citations in OpenAlex.
- Prognostic potential of albumin to fibrinogen ratio in multiple myeloma patients.Annals of hematology · 2025Article
- Decoding iron deficiency in cancer: mechanisms, immune modulation, and therapeutic potential.Frontiers in nutrition · 2025Review
- Changes in RDW according to prognostic predictors in newly diagnosed multiple myeloma.Scientific reports · 2024Article
- Calculated haemorheological profile and laboratory parameters in new diagnosed multiple myeloma patients: retrospective analysis according to survival.Therapeutic advances in hematology · 2024Article
- GDF-15 and hepcidin as a therapeutic target for anemia in chronic kidney disease.Italian journal of pediatrics · 2023Article
- Calculated Whole Blood Viscosity and Albumin/Fibrinogen Ratio in Patients with a New Diagnosis of Multiple Myeloma: Relationships with Some Prognostic Predictors.Biomedicines · 2023Article
- Mesenchymal stromal cell senescence in haematological malignancies.Cancer metastasis reviews · 2023Review
- The Key Role of Hepcidin-25 in Anemia in Multiple Myeloma Patients with Renal Impairment.Medicina (Kaunas, Lithuania) · 2022Article
- Hepcidin and GDF-15 are potential biomarkers of iron deficiency anaemia in chronic kidney disease patients in South Africa.BMC nephrology · 2020Article
- Associations Between Cardiac Biomarkers and Cardiac Structure and Function in CKD.Kidney international reports · 2020Article
- Evaluating the Relationship of GDF-15 with Clinical Characteristics, Cardinal Features, and Survival in Multiple Myeloma.Mediators of inflammation · 2020Article
- New Biomarkers of Ferric Management in Multiple Myeloma and Kidney Disease-Associated Anemia.Journal of clinical medicine · 2019Review
- Limitations of Serum Ferritin in Diagnosing Iron Deficiency in Inflammatory Conditions.International journal of chronic diseases · 2018Review
- The relationship between systemic iron homeostasis and erythropoiesis.Bioscience reports · 2017Review
- Anaemia of Chronic Disease: An In-Depth Review.Medical principles and practice : international journal of the Kuwait University, Health Science Centre · 2017Review
- Iron and cancer: recent insights.Annals of the New York Academy of Sciences · 2016Review
- Modulation of hepcidin to treat iron deregulation: potential clinical applications.Expert review of hematology · 2016Review
- The three isoforms of hepcidin in human serum and their processing determined by liquid chromatography-tandem mass spectrometry (LC-tandem MS).International journal of hematology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple myeloma (MM) is a malignant disease of plasma cells and is often accompanied by anemia which may influence its progression and survival. The mechanism of anemia of chronic disease (ACD) in which iron homeostasis is impaired underlies that of MM-related anemia. In this study, we analyzed the role of hepcidin which is the main mediator of ACD and ACD-related cytokines in peripheral blood of MM patients. We showed that HAMP mRNA and growth differentiation factors 15 (GDF15) mRNA expressions in peripheral blood mononuclear cells (PBMCs) and plasma hepcidin, GDF15, interleukin-6 and erythropoietin in MM patients all increased significantly as compared to those in controls. In MM patients, the expression of HAMP mRNA showed a positive correlation with serum ferritin level, and a negative correlation with hemoglobin level. The levels of plasma hepcidin and GDF15 were significantly decreased in MM patients who achieved complete remission after six cycles VD (bortezomib + dexamethasone) regimen chemotherapy. These data indicated that overexpression of HAMP mRNA in PBMCs significantly correlated with increased plasma hepcidin level and may be involved in the pathogenesis of MM-related anemia. Furthermore, the levels of plasma hepcidin and GDF15 may be valuable in assessing the progress of MM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.